Therefore, in tolDC phase I clinical trials for MS patients, a cocktail of myelin peptides containing the most relevant autoreactive MOG, PLP, and MBP peptides seems to be a better strategy.72,73 In fact, the three phase I clinical trials of peptide-loaded tolDCs in MS have employed a similar approach using a pool of myelin peptides (NCT02283671, NCT02903537, and NCT02618902) (Table 2). Here, MOG is linked to myeloid sarcoma.